Year: 2019
Type: article
Abstract: : Fibrolamellar carcinoma is a rare liver cancer, which primarily afflicts adolescents and young adults worldwide and is frequently lethal. Given the rarity of this disease, patient recruitment for clinical trials remains a challenge. In November 2017, the Second Fibrolamellar Cancer Foundation Scientific Summit (Stamford, CT, USA) provided an opportunity for investigators to discuss recent advances in the characterization of the disease and its surrounding liver and immune context. The Fibrolamellar Cancer Foundation has thus set out a road map to identify and test therapeutic targets in the most efficient possible manner. Keywords: fibrolamellar carcinoma, liver cancer, adolescent, young adult, fusion oncogene, cyclic AMP-dependent protein kinase catalytic subunit, heat shock protein 40
DOI: 10.2147/jhc.s194764
Authors: Edward R. Kastenhuber, John Craig, Jon Ramsey, Kevin Sullivan, Julien Sage, Sofia de Oliveira, Kimberly J. Riehle, John D. Scott, John Gordan, Nabeel Bardeesy, Ghassan K. Abou-Alfa
Institutions: Memorial Sloan Kettering Cancer Center, Fibrolamellar Cancer Foundation, University of Vermont, University of Washington, Stanford Medicine, Stanford University, University of Wisconsin–Madison, University of California, San Francisco, Harvard University, Massachusetts General Hospital, Weill Cornell Medicine
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,836
OpenAlex ID: W2913313778